ImmunityBio (NasdaqGS:IBRX) completed enrollment ahead of schedule in a Phase 2 trial of Anktiva plus BCG for BCG naïve non muscle invasive bladder cancer. Interim data from the trial show stronger ...
Discover the top 3 undervalued Household Durables stocks for Friday, February 27 based on AAII’s Stock Grades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results